Upregulation of endothelin-1 binding in tissues of salt-loaded stroke-prone spontaneously hypertensive rats

Abstract

Upon maintained on a 1% NaCl drinking solution beginning at 7 weeks of age, the stroke-prone spontaneously hypertensive rat (SHRsp) developed severe hypertension and stroke; most died by 16 weeks. The mechanism by which these diseases evolve remains unclear. Endothelin-1 (ET-1) is a potent, peptidic vasoconstrictor and is implicated in the pathogenesis of various cardiovascular, renal, and central nervous system diseases. The purpose of the present study was to compare the binding of [125I]ET-1 to the brain, heart, kidney, liver, and spleen membrane preparations of 16-week-old SHRsp and age-matched normotensive Wistar-Kyoto rats (WKY). The KD values for [125I]ET-1 binding to the corresponding tissues of the two strains were not significantly different, except in the brain (SHRsp: 17 +/- 1 pM; WKY: 24 +/- 1 pM). In contrast, the Bmax values measured in the brain, heart, kidney, and liver of SHRsp were 1.5- to 2.1-fold greater than those of their WKY counterparts. Competition of [125I]ET-1 binding to the membrane preparations by the specific ETA receptor antagonist BQ-123 or the specific ETB receptor agonist sarafotoxin S6c revealed a similar proportion of ETA and ETB receptor subtypes in the corresponding tissues of the two rat strains. These results indicate that ET-1 binding is upregulated in SHRsp and suggest that ET-1 may play a pathophysiological role in this animal model of genetic hypertension.

Blood brain barrier breakdown as the starting point of cerebral small vessel disease? - New insights from a rat model

“…SHRSP were obtained by selective breeding from spontaneously hypertensive rats (SHR) for the development of spontaneous infarcts [11-13] and exhibit an overactivity of the renin-angiotensin-system [14], a detectability of renin within the vascular walls [15], an altered endothelin system [16] and an increased sympathetic nerve activity [17] potentiated by elevated levels of prostaglandins [18] in their sum leading to an early development of chronic severe arterial hypertension [12]. …”

Changing Pathology with Changing Drugs: Skin Cancer

“…Imatinib functions as a multikinase competitive inhibitor, competing with ATP for the binding site of the tyrosine kinase domain of the KIT receptor. Imatinib can only bind to the nucleotide binding site within the juxtamembrane domain when the DFG (Asp 810 , Phe 811 , Gly 812 ) motif is present [162,163] . Imatinib has been tried in melanoma patients in several clinical studies.…”

Acrolentiginous melanomas

“…It shows activity against several receptors such as bcr-abl, KIT, platelet-derived growth factor receptors a and b, Abelson murine leukemia, and Abelson-related gene [64]. Imatinib can only bind to the nucleotide-binding site within the juxtamembrane domain, when the DFG (ASP 810 , Phe 811 , Gly 812 ) (D: ASP, F: Phe, G: Gly) motif is present [68,69]. Imatinib can only bind to the nucleotide-binding site within the juxtamembrane domain, when the DFG (ASP 810 , Phe 811 , Gly 812 ) (D: ASP, F: Phe, G: Gly) motif is present [68,69].…”